Format

Send to

Choose Destination
Nat Commun. 2018 Mar 23;9(1):1216. doi: 10.1038/s41467-018-03609-x.

The orphan GPR50 receptor promotes constitutive TGFβ receptor signaling and protects against cancer development.

Author information

1
Inserm, U1016, Institut Cochin, Paris, 75014, France.
2
CNRS UMR 8104, Paris, 75014, France.
3
Université Paris Descartes, Université Sorbonne Paris Cité, Paris, 75006, France.
4
Hôpital Necker, CNRS UMR 8147, Paris, 75015, France.
5
Jean-Pierre Aubert Research Center, U837, Lille, France.
6
Plateforme Proteomique 3P5 de l'Université Paris Descartes, Paris, 75014, France.
7
Sorbonne Université, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.
8
Institut de Recherches SERVIER, Suresnes, 92150, France.
9
Inserm, U1016, Institut Cochin, Paris, 75014, France. ralf.jockers@inserm.fr.
10
CNRS UMR 8104, Paris, 75014, France. ralf.jockers@inserm.fr.
11
Université Paris Descartes, Université Sorbonne Paris Cité, Paris, 75006, France. ralf.jockers@inserm.fr.

Abstract

Transforming growth factor-β (TGFβ) signaling is initiated by the type I, II TGFβ receptor (TβRI/TβRII) complex. Here we report the formation of an alternative complex between TβRI and the orphan GPR50, belonging to the G protein-coupled receptor super-family. The interaction of GPR50 with TβRI induces spontaneous TβRI-dependent Smad and non-Smad signaling by stabilizing the active TβRI conformation and competing for the binding of the negative regulator FKBP12 to TβRI. GPR50 overexpression in MDA-MB-231 cells mimics the anti-proliferative effect of TβRI and decreases tumor growth in a xenograft mouse model. Inversely, targeted deletion of GPR50 in the MMTV/Neu spontaneous mammary cancer model shows decreased survival after tumor onset and increased tumor growth. Low GPR50 expression is associated with poor survival prognosis in human breast cancer irrespective of the breast cancer subtype. This describes a previously unappreciated spontaneous TGFβ-independent activation mode of TβRI and identifies GPR50 as a TβRI co-receptor with potential impact on cancer development.

PMID:
29572483
PMCID:
PMC5865211
DOI:
10.1038/s41467-018-03609-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center